Unicar-Therapy Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Shanghai China

Primary Industry

Pharmaceuticals

About

Established in 2015 and based in Shanghai, China, Unicar-Therapy is a biotechnology company that focuses on the development of CAR-T and other cell/gene therapy technologies and products. Unicar-Therapy has won many honors, such as the China Cell Therapy Enterprise Rapid Growth Award, the 2019 Future Medical Top 100 - Top 100 China Innovative Medicine List, and the 2020 Top 100 Chinese Pharmaceutical Innovation Enterprises. Unicar-Therapy cooperated with Hainan Haiyao to build a gene and cell therapy center in Hainan. The company is committed to the development of CAR-T and other cell/gene therapy products. It uses CAR-T therapy, builds antibody screening platforms and GMP production bases to develop CAR-T products for tumor treatment, and has completed more than 1,000 CAR-T clinical studies and treatments with the hematology departments of many domestic hospitals. In September 2020, Yucardi received approval for a new CAR-T2.0 product, SSCART-19 injection, in a formal clinical trial.

Current Investors

Apricot Capital, Shanghai Yuchen Investment, Alwin Capital

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Healthcare IT, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.unicar-therapy.com

Verticals

HealthTech, Manufacturing

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.